1h Free Analyst Time
The erythropoietin stimulating agents market is forecasted to grow by USD 4.50 billion during 2023-2028, accelerating at a CAGR of 8.5% during the forecast period. The report on the erythropoietin stimulating agents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by presence of large pool of ckd patients, rising applications in hiv infections and end-stage renal disorder, and risks of thrombosis, during surgeries, and pure red cell aplasia.
The erythropoietin stimulating agents market is segmented as below:
By Type
- Epoetin alfa
- Epoetin beta
- Darbepoetin alfa
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the erythropoietin stimulating agents market covers the following areas:
- Erythropoietin Stimulating Agents Market sizing
- Erythropoietin Stimulating Agents Market forecast
- Erythropoietin Stimulating Agents Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global erythropoietin stimulating agents market: 3SBio Inc., Akebia Therapeutics, Amgen Inc., Biocon Ltd., Biosidus SA, Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., Nanogen Pharmaceutical Biotechnology, NephroPlus, Novartis AG, Pfizer Inc., Reliance Industries Ltd., Renal Project, Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing number of ckd dialysis centers in developing economies."
According to the report, one of the major drivers for this market is the presence of large pool of ckd patients.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc.
- Akebia Therapeutics
- Amgen Inc.
- Biocon Ltd.
- Biosidus SA
- Dr Reddys Laboratories Ltd.
- F. Hoffmann La Roche Ltd.
- Johnson and Johnson Services Inc.
- Nanogen Pharmaceutical Biotechnology
- NephroPlus
- Novartis AG
- Pfizer Inc.
- Reliance Industries Ltd.
- Renal Project
- Thermo Fisher Scientific Inc.
- Zydus Lifesciences Ltd.
